Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors
The goal of the current study was to investigate the safety and determine the maximum tolerated dose (MTD) of S-1 in combination with oxaliplatin and epirubicin in patients with advanced or metastatic solid tumors.
Patients With Advanced or Metastatic Solid Tumors
DRUG: Teysuno (S1) in combination with epirubicin and oxaliplatin
The highest dose level at which less than 33% of the patients experienced a dose-limiting toxicity (DLT) during Cycle 1., 21 days
The goal of the current study was to investigate the safety and determine the maximum tolerated dose (MTD) of S-1 in combination with oxaliplatin and epirubicin in patients with advanced or metastatic solid tumors.